EUVIMEDEUVIMED entdecken
Open Access

Immune suppression sustained allograft acceptance requires PD1 inhibition of CD8+ T cells

Hilary Miller-Handley iD, Gavin Harper, Giang Pham iD, Lucien H Turner iD, Tzu-Yu Shao iD, Abigail E Russi, John J Erickson iD, Mandy L Ford iD, Koichi Araki, Sing Sing Way iD

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkae007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Hilary Miller-Handley und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Center for Inflammation and Tolerance, Department of Pediatrics, Cincinnati Children's Hospital, University of Cinci…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor, Graft Rejection, Skin Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, University of Cincinnati Center for Clinical and Translational Science, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Organ transplant recipients require continual immune-suppressive therapies to sustain allograft acceptance. Although medication nonadherence is a major cause of rejection, the mechanisms responsible for graft loss in this clinically relevant context among individuals with preceding graft acceptance remain uncertain. Here, we demonstrate that skin allograft acceptance in mice maintained with clinically relevant immune-suppressive therapies, tacrolimus and mycophenolate, sensitizes hypofunctional PD1hi graft-specific CD8+ T cells. Uninterrupted immune-suppressive therapy is required because drug discontinuation triggers allograft rejection, replicating the requirement for immune-suppressive therapy adherence in transplant recipients. Graft-specific CD8+ T cells in allograft-accepted mice show diminished effector differentiation and cytokine production, with reciprocally increased PD1 expression. Allograft acceptance–induced PD1 expression is essential, as PDL1 blockade reinvigorates graft-specific CD8+ T cell activation with ensuing allograft rejection despite continual immune-suppressive therapy. Thus, PD1 sustained CD8+ T cell inhibition is essential for allograft acceptance maintained by tacrolimus plus mycophenolate. This necessity for PD1 in sustaining allograft acceptance explains the high rates of rejection in transplant recipients with cancer administered immune checkpoint inhibitors targeting PD1/PDL1, highlighting shared immune suppression pathways exploited by tumor cells and current therapies for averting allograft rejection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesProgrammed Cell Death 1 ReceptorGraft RejectionSkin TransplantationGraft SurvivalAnimalsMiceMice, Inbred C57BLAllograftsTacrolimusImmunosuppressive AgentsMycophenolic AcidMice, Inbred BALB C

Stichwörter der Autor:innen

T cells (cells)costimulation (processes)rodent (animal)transplantation (processes)

Substanzen

Programmed Cell Death 1 ReceptorPdcd1 protein, mouseTacrolimusImmunosuppressive AgentsMycophenolic Acid

Autor:innen und Institutionen

  • Division of Infectious Diseases, Center for Inflammation and Tolerance, Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
  • Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
  • Division of Gastroenterology, Hepatology and Advanced Nutrition, Department of Pediatrics, Cincinnati Children's Hospital,University of Cincinnati College of Medicine, Cincinnati, OH, United States.
  • Division of Neonatology, Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
  • Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, United States.

ORCID-Profile: Hilary Miller-Handley, Giang Pham, Lucien H Turner, Tzu-Yu Shao, John J Erickson, Mandy L Ford, Sing Sing Way

Förderung

  • NIDDK NIH HHS
  • University of Cincinnati Center for Clinical and Translational Science
  • NIAID NIH HHS
  • American Society of Transplantation
  • National Institutes of Allergy and Infectious Diseases
  • March of Dimes Foundation Ohio Collaborative for Prematurity Research
  • University of Cincinnati College of Medicine Internal Medicine Scholarly Training for Academic Research
  • Burroughs Wellcome Fund Investigator in Infectious Disease

Zitieren

APA

Miller-Handley, H., Harper, G., Pham, G., Turner, L. H., Shao, T. Y., Russi, A. E., Erickson, J. J., Ford, M. L., Araki, K., & Way, S. S. (2025). Immune suppression sustained allograft acceptance requires PD1 inhibition of CD8+ T cells. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkae007

Vancouver

Miller-Handley H, Harper G, Pham G, Turner LH, Shao TY, Russi AE, et al. Immune suppression sustained allograft acceptance requires PD1 inhibition of CD8+ T cells. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkae007

BibTeX
@article{MillerHandley2025,
  author = {Miller-Handley, Hilary and Harper, Gavin and Pham, Giang and Turner, Lucien H and Shao, Tzu-Yu and Russi, Abigail E and Erickson, John J and Ford, Mandy L and Araki, Koichi and Way, Sing Sing},
  title = {Immune suppression sustained allograft acceptance requires PD1 inhibition of CD8+ T cells},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkae007}
}
Kostenlos starten →